Ascendis Pharma company information, Employees & Contact Information

Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 Yahoo Finance

New 3-Year Phase 3 Data Confirmed Sustained Response to GlobeNewswire

Biotech Leader Ascendis Pharma Set for Key Presentation at 2025 Wells Fargo Healthcare Conference Stock Titan

Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference Yahoo Finance

Ascendis Pharma Reports Second Quarter 2025 Financial Results GlobeNewswire

Ascendis Pharma Q2 2025 Earnings Call: Key Financial Results Coming August 7 After Market Close Stock Titan

Ascendis Pharma Reports First Quarter 2025 Financial Results GlobeNewswire

Ascendis Pharma Outlines Strategic Roadmap for Revenue Growth and Key Milestones in 2025 Nasdaq

Ascendis Pharma's SKYTROFA Surges 84% in Volume, Driving €364M Revenue for 2024 Stock Titan

FDA Accepts TransCon® CNP NDA for Priority Review GlobeNewswire

Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs GlobeNewswire

Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025 Yahoo Finance

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025 GlobeNewswire

New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors Yahoo Finance

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results GlobeNewswire

FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency GlobeNewswire

Ascendis Pharma and Novo Nordisk Sign Collaboration for GlobeNewswire

Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism Yahoo Finance

Er-Kim Extends Exclusive Distribution Agreement with Ascendis Pharma A/S to Expand Commercialization of Its Endocrinology Portfolio to Eurasian Markets Yahoo Finance

Ascendis Submits Marketing Authorisation Application to the GlobeNewswire

Ascendis Pharma Launches SKYTROFA® (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency Yahoo Finance

TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial Yahoo Finance

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement GlobeNewswire

Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia GlobeNewswire

Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) GlobeNewswire

Ascendis Pharma: Danish Blockbuster Hunter (NASDAQ:ASND) Seeking Alpha

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025 Stock Titan

Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan GlobeNewswire

Ascendis Pharma Q1 Earnings: Dual Drug Success Powers €101M Revenue as Pipeline Advances Stock Titan

New Data Shows Improvements in Growth and Bone Morphometry GlobeNewswire

Ascendis Pharma A/S Announces Equity Investment in VISEN Pharmaceuticals Yahoo Finance

FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the GlobeNewswire

YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults GlobeNewswire

Ascendis Pharma A/S Announces Full Year 2021 Financial Results and Business Update Conference Call on March 2 GlobeNewswire

FDA Approves YORVIPATH® (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults GlobeNewswire

Ascendis Pharma A/S Announces U.S. Food and Drug GlobeNewswire

Ascendis Pharma A/S Appoints Scott T. Smith as Chief Financial Officer PR Newswire

Ascendis Pharma A/S Announces Extension of U.S. Food and GlobeNewswire

Ascendis Pharma, a global biopharmaceutical company specialising in rare endocrine and other diseases, opens new office for the UK and Ireland PharmiWeb.com

Ascendis Pharma A/S to Present at Upcoming Investor Conferences PR Newswire

Ascendis Pharma A/S Announces Multiple TransCon Growth Hormone Presentations at the European Society of Paediatric Endocrinology Annual Meeting PR Newswire

Ascendis Pharma A/S Announces Pricing of Initial Public Offering PR Newswire